Ads
related to: fasenra asthma medication dosage
Search results
Results From The WOW.Com Content Network
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor . It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca. [3] [4] Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
The most common class of quick-relief asthma medications is known as bronchodilators. ... these devices are pre-packed with a measured amount of medication inside that is released in dose ...
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ transplant recipients who became steroid resistant. [39] Hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and ...
Ads
related to: fasenra asthma medication dosage